title: Raltegravir and etravirine are active against HIV type 1 group O.
abstract: Abstract The activity of raltegravir and etravirine was assessed in vitro in HIV-1 group O isolates. Despite the presence of some natural polymorphisms associated with resistance to raltegravir (V72I, L74I, S153A, V201I, and T206S) and etravirine (G190A), both drugs showed significant antiviral activity. Subsequently, the clinical benefit was shown in an HIV-1 group O-infected individual in whom enfuvirtide was replaced by raltegravir. Therefore, individuals infected with HIV-1 group O might benefit from raltegravir and/or etravirine therapy.
authors.affiliation: Department of Infectious Disease, Hospital Carlos III, Madrid, Spain. veronica.briz@terra.es
authors.forename: Verónica
authors.initials: V
authors.lastname: Briz
authors.forename: Carolina
authors.initials: C
authors.lastname: Garrido
authors.forename: Eva
authors.initials: E
authors.lastname: Poveda
authors.forename: Judit
authors.initials: J
authors.lastname: Morello
authors.forename: Pablo
authors.initials: P
authors.lastname: Barreiro
authors.forename: Carmen
authors.initials: C
authors.lastname: de Mendoza
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D020125:Mutation, Missense; D009570:Nitriles; D011724:Pyridazines / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines; D011760:Pyrrolidinones / Q000494:pharmacology* / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D012367:RNA, Viral; C451734:etravirine; D000068898:Raltegravir Potassium